Member Since 2008
President, Global Oncology Business Unit
Teresa Bitetti is President of the Global Oncology Business Unit. She is responsible for oncology business activities in ten countries, including the U.S., Japan, U.K., Ireland, Germany, France, Italy, Spain, Portugal, and Canada.
Before joining Takeda, Teresa Bitetti was the Senior Vice President, Head of Worldwide Oncology Commercialization at Bristol-Myers Squibb. In this role, Teresa significantly enhanced the long-term strategic direction of the immuno-oncology portfolio. In addition, she further enhanced the model of collaboration with the R&D team to ensure the long-term success of its marketed and pipeline Oncology products. In the company, some of her key leadership roles have included Senior Vice President and Head of U.S. Oncology, President and GM of BMS Canada, and Worldwide Head of the BMS Virology business.
Prior to joining Bristol-Myers Squibb, Teresa held various roles of increasing responsibility at Mobil Oil Corporation, where she was part of the Capital Markets Group and was responsible for the investment of Mobil’s worldwide pension assets.
Over Teresa’s 20+ year career, she has been highly recognized for her adept ability to mobilize teams to deliver exceptional performance. Her notable awards include Medical Marketing Association 2003 Pharmaceutical Marketer of the Year Award and Medical Marketing & Media 2016 Hall of Femme Honoree.
Teresa holds a BA in Classical Civilization from Wellesley College and an MBA in Finance from Darden School of Business at University of Virginia.
CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Task force Participation
Task Force Member(s): Nancy M. Shostack, Director, Head of Benefits and Mobility
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Dean Bottino, PhD, Clinical Translational Modeling & Simulation Leader
Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium
At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more — to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.